Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
PMC-309
i
Other names:
PMC-309, PMC-309a-z
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
PharmAbcine
Drug class:
VISTA antagonist
Related drugs:
‹
CA-170 (0)
HMBD-002 (0)
KVA12123 (0)
SNS-101 (0)
CI-8993 (0)
CA-170 (0)
HMBD-002 (0)
KVA12123 (0)
SNS-101 (0)
CI-8993 (0)
›
Associations
News
Trials
Filter by
Latest
1year
KEYNOTE-E80: Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 (clinicaltrials.gov)
P1, N=67, Not yet recruiting, PharmAbcine | Phase classification: P1a/1b --> P1
1 year ago
Phase classification • Metastases
|
CD4 (CD4 Molecule)
|
Keytruda (pembrolizumab) • PMC-309
1year
KEYNOTE-E80: Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 (clinicaltrials.gov)
P1a/1b, N=67, Not yet recruiting, PharmAbcine | Initiation date: Aug 2023 --> Nov 2023
1 year ago
Trial initiation date • Metastases
|
CD4 (CD4 Molecule)
|
Keytruda (pembrolizumab) • PMC-309
over1year
KEYNOTE-E80: Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 (clinicaltrials.gov)
P1a/1b, N=67, Not yet recruiting, PharmAbcine
over 1 year ago
New P1 trial • Metastases
|
CD4 (CD4 Molecule)
|
Keytruda (pembrolizumab) • PMC-309
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login